



**Sociedad Argentina de
Terapia Radiante Oncológica**

V Best of ASTRO



SCIENCE OF TODAY
HOPE FOR TOMORROW

ARGENTINA

12, 13 y 14 de Mayo 2021

**Modalidad Virtual
Ciudad Autónoma de Buenos Aires**



SCIENCE OF TODAY
HOPE FOR TOMORROW

Este evento se realiza con licencia de American Society of Radiation Oncology “ASTRO” con el objetivo de difundir los trabajos con mejor puntuación del ASTRO Annual Meeting del año 2020 - USA, Modalidad Virtual

Comisión Directiva 2020 - 2022



Presidente

Dr. Gustavo Ferraris

Vicepresidente

Dra. Verónica Vázquez Balcarce

Secretario General

Dra. María Fernanda Díaz Vázquez

Secretario de Actas

Dr. José Máximo Barros

Prosecretario

Dra. Claudia Benavento

Tesorero

Dra. Carmen Castro

Protesorero

Dr. Oscar Gómez Orrego

Vocales Titulares

Dr. Jorge Palazzo

Dra. Luisa Rafailovici

Dra. Mabel Sardi

Dr. Carlos Cardello

Dra. Patricia Bruno

Dra. Carolina Chacón

Vocales Suplentes

Dr. Lucas Causa

Dr. Marcelo Andrade Irusta

Dra. María Cecilia Coll

Dr. Federico Díaz

Dra. María José Girola

Dra. Claudia De Angelis

Dr. Carlos Donoso

Órgano de fiscalización

Revisores de Cuentas Titulares

Dr. Javier Otero

Dr. Mauro Mattio

Dra. Vanesa Krakobsky

Revisor de Cuentas Suplente

Dr. Ignacio Sisamón

Dra. Luz Font

Comité de Ética

Dra. Ana Mabel Martínez

Dra. Estela Broda

Dr. Ricardo Alva

Dr. Hugo Donato

Comité Científico

Dra. Luisa Rafailovici

Dra. María Luisa Filomía

Dra. Mabel Sardi

Información General

Secretaría SATRO:

Sra. Rosario Val

Cel / Whatsapp: +54911 6369-6348

e-mail: satro@fibertel.com.ar // xina_arg@hotmail.com

Sitio web: www.satro-radioterapia.com.ar

Facebook: Sociedad Argentina de Terapia Radiante Oncologic

Instagram: socterapiaradiante

YouTube: Satro Radioterapia

Secretaría Evento:

IV Eventos – Sra. Inés Vuoto

Cel / Whatsapp: +54911 5035-0701

e-mail: info@iveventos.com

Invitados Extranjeros



Dra. Higinia Cardenes
New York, Estados Unidos
Profesora Oncología Radioterápica
Weill Cornell University
New York Presbyterian Hospital



Dr. Marcos Santos
Goiânia, Brasil
Clínica Confiar



Dr. Nicolás Isa
Santiago, Chile
Clínica Oncológica IRAM



Dr. Gustavo Sarría
Lima, Perú
Sub Jefe Institucional
Instituto Nacional de
Enfermedades Neoplásicas



Dr. Aldo Quarneti
Montevideo, Uruguay
Profesor Titular de la Cátedra
de Oncología Radioterápica,
Facultad de Medicina de la
Universidad del Uruguay

Simposio Craveri



Dr. Héctor Del Valle
Buenos Aires, Argentina
Miembro de la Dirección Médica de Craveri
Especialista en Medicina de la Industria Farmacéutica
Asesor Médico Craveri SAIC

Auspicios Académicos



Asociación Argentina De Ginecología Oncológica



Fundada en 1923



ASOCIACIÓN DE ONCOLÓGOS CLÍNICOS DE CÓRDOBA



Sociedad Argentina de Cancerología
Asociación Civil



- Facultad de Medicina, Universidad de la República Oriental del Uruguay
- Sociedad de Obstetricia y Ginecología de Buenos Aires

Miércoles 12 de Mayo

17:00 – 17:03 hs. Acto de Apertura Dr. Gustavo Ferraris
Presidente de SATRO

17:03 – 18:03 hs. Módulo 1: Cáncer de Cabeza y Cuello

17:03 – 17:08 hs. Presidente: Dr. Diego Fernández,
Centro de Radioterapia Dean Funes, Córdoba

Coordinador: Dr. Jorge Palazzo, Vidt Centro Médico, Tucumán

Disertantes:

17:08 – 17:13 hs. Dr. Carlos Cardiello, Vidt Centro Médico, Buenos Aires

Abstract 178: Risk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors treated with definitive radiotherapy: A Retrospective Cohort Study among 1,988 Survivors

17:13 – 17:18 hs. Dra. Silvina Lemoine, Hospital Alemán, Buenos Aires

Abstract 179: Development of Advanced Preselection Tools to Reduce Unnecessary Plan Comparisons in Model-Based Selection of Head and Neck Cancer Patients for Proton Therapy

17:18 – 17:23 hs. Dr. Sergio Quiceno, Vidt Centro Médico, Buenos Aires

Abstract 181: Defining Radiotherapy (RT) Coverage for Non-Melanoma Skin Cancer (NMSC) Using Mohs Micrographic Surgery (MMS) Margins

17:23 – 17:28 hs. Dra. Cecilia Coll, Instituto Privado de Radioterapia Cuyo, Mendoza

Abstract 222: Nivolumab and ipilimumab combined with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: in-field toxicity analysis of a phase I clinical trial

17:28 – 17:33 hs. Dr. Matías Zapata, Vidt Centro Médico, Buenos Aires

Abstract 226: Efficacy and Safety of Aprepitant for the Prevention of Nausea and Emesis during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC): A Phase 2 Trial

17:33 – 18:03 hs. Mesa de Discusión:

Coordinador: Dr. Jorge Palazzo (RT)

Panelistas: Dr. Diego Fernández (RT), Dr. Carlos Cardiello (RT), Dr. Sergio Quiceno (RT), Dra. Silvina Lemoine (RT), Dra. Cecilia Coll (RT), Dr. Matías Zapata (RT)
Dr. Agustín Falco (Oncología Clínica), Inst. Alexander Fleming, Buenos Aires
Dra. Bárbara Berenstein (Cirugía Oncológica), Instituto Ángel Roffo, Bs. As.

Miércoles 12 de Mayo

18:05 – 19:20 hs. Módulo 2: Cáncer de Pulmón

18:05 – 18:10 hs. Presidente: Dra. Berta Roth, CEMIC, Buenos Aires

Coordinador: Dr. Aldo Quarneti,
Hospital Pereira Rossell, Montevideo, Uruguay

Disertantes:

18:10 – 18:20 hs. Dr. Nicolás Isa, Clínica IRAM, Santiago, Chile

Abstract 3: RTOG0617 to externally validate blood cell ERCC1/2 genotypic signature as a radiosensitivity biomarker for both tumor and normal tissue for individualized dose prescription

Abstract 5: Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial

18:20 – 18:30 hs. Dr. Alejandro Chinellato, Grupo Gamma, Rosario, Santa Fe

Abstract 147: Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Abstract 219: Individualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601

18:30 – 18:40 hs. Dr. Carlos Pizzo, Terapia Radiante Cumbres, Rosario, Santa Fe

Abstract 220: A Phase III Randomized Trial of Palliative Radiation for Advanced Central Lung Tumours with Intentional Avoidance of the Esophagus (PROACTIVE)

Abstract LBA 3: Patterns of Disease Progression After Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

18:40 – 18:50 hs. Dr. Pablo Converso, Vidt Centro Médico, Buenos Aires

Abstract 1044: Assessment of Coronary Artery Calcification Burden as a Risk Factor for Cardiac Toxicity in Patients Treated on Radiation Dose-escalation Trials for Stage III Non-small-cell Lung Cancer

Abstract 1045: Statin Use and Major Adverse Cardiac Events among High Cardiac Risk Patients with Lung Cancer Receiving Radiotherapy

18:50 – 19:20 hs. Mesa de Discusión:

Coordinador: Dr. Aldo Quarneti (RT)

Panelistas: Dra. Berta Roth (RT), Dr. Nicolás Isa (RT), Dr. Alejandro Chinellato (RT),
Dr. Carlos Pizzo (RT), Dr. Pablo Converso (RT)
Dr. José Máximo Barros, **Radioncólogo**, Hospital Universitario Austral, Bs. As.
Dr. Claudio Martín, **Oncología Clínica**, Instituto Alexander Fleming, Bs. As.
Dr. Gustavo Bondulich, **Cirugía Oncológica**, Clínica San Camilo, Bs. As.

19:20 – 19:50 hs. Actividad a Confirmar

19:50 – 20:55 hs. Módulo 3: Cáncer Genitourinario

19:50 – 19:55 hs. Presidente: Dr. Jorge Chiozza, Vidt Centro Médico, Buenos Aires

Coordinadora: Dra. Carolina Chacón,
Instituto Alexander Fleming, Buenos Aires

Disertantes:

19:55 – 20:05 hs. Dr. Darío Llanos, Centro de Radioterapia, San Juan

Abstract 32: Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

Abstract 35: Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

20:05 – 20:15 hs. Dr. Marcelo Andrade Irusta, Vidt Centro Médico, Buenos Aires

Abstract 126: Five-Year Toxicity After EBRT For Localized Prostate Cancer With or Without a Simultaneously Integrated Focal Boost up to 95Gy: Results of a Randomized Controlled Trial

Abstract 128: Ultra-Hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST Trial

20:15 – 20:20 hs. Dra. Marcela de la Torre, Hospital de Clínicas, Buenos Aires

Abstract 127: An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

20:20 – 20:25hs. Dra. Carmen Castro, Hospital Alemán, Buenos Aires

Abstract LBA 1: Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (¹⁸F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer

20:25 – 20:55 hs. Mesa de Discusión:

Coordinadora: Dra. Carolina Chacón (RT)

Panelistas: Dr. Jorge Chiozza (RT), Dr. Darío Llanos (RT), Dra. Carmen Castro (RT),
Dr. Marcelo Andrade Irusta (RT), Dra. Marcela de la Torre (RT)
Dr. Santiago Bella (Oncología Clínica), Sanatorio Allende, Córdoba
Dr. Pablo Martínez (Urología), Hospital Italiano, Buenos Aires
Dr. Lisandro Paganini (Especialista Imágenes), Inst. Alexander Fleming, BA

17:00 – 18:10 hs. Módulo 4: Cáncer Gastrointestinal

17:00 – 17:05 hs. Presidente: Dra. Laura Giglio, Hospital Italiano, Buenos Aires

**Coordinadora: Dra. Higinia Cardenes,
Weill Cornell University, New York, USA**

Disertantes:

**17:05 – 17:15 hs. Dra. Claudia Benavento,
Consultorio Privado de Radiaciones Gral, San Martín, Bs. As.**

Abstract 95: Nonoperative management versus surgery in patients with complete endoscopic response to neoadjuvant therapy for rectal cancer

Abstract 96: Complete clinical response after short-course radiation and sequential multi-agent chemotherapy for non-operative treatment of rectal adenocarcinoma

17:15 – 17:25 hs. Dr. Carlos Donoso, Centro de Radioterapia CITO, San Isidro, Bs.As.

Abstract 174: A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer

Abstract 175: Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of A Prospective Biomarker Study

17:25 – 17:35 hs. Dra. Mabel Sardi, Instituto Mevaterapia, Buenos Aires

Abstract 1070: Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma

Abstract 3321: Stereotactic Body Radiotherapy vs Transarterial Chemoembolisation in locally advanced hepatocellular carcinoma (HERACLES: HEpatocellular carcinoma stereotactic Radiotherapy Clinical Efficacy Study)

17:35 – 17:40 hs. Dr. Augusto Alva, Instituto Mevaterapia, Buenos Aires

Abstract 1072: Relationship of Dose to Vascular Target Volumes and Local Failure in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemoradiation

17:40 – 18:10 hs. Mesa de Discusión:

Coordinadora: Dra. Higinia Cardenes (RT)

Panelistas: Dra. Laura Giglio (RT), Dra. Claudia Benavento (RT), Dr. Carlos Donoso (RT), Dra. Mabel Sardi (RT), Dr. Augusto Alva (RT), Dr. Mario Barugel (Oncología Clínica), Ex Médico Hospital Udaondo, Bs. As. Dr. Eduardo Huertas (Cirugía), Instituto Alexander Fleming, Buenos Aires

18:10 – 19:25 hs. Módulo 5: Hematología Oncológica

18:10 – 18:15 hs. Presidente: Dra. Carolina Fernández Bibiloni, EMTRO, Olavarría, BA

**Coordinador: Dr. Juan Galarraga,
Centro de Oncología y Radioterapia, Mar del Plata, BA**

Disertantes:

**18:15 – 18:25 hs. Dr. Oscar Gómez Orrego,
Centro de Radiaciones Gral. San Martín, Buenos Aires**

Abstract 243: Assessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy

Abstract 1050: An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?

18:25 – 18:35 hs. Dr. Luis Carvajal, Dean Funes La Plata, Buenos Aires

Abstract 1054: Efficacy of Low Dose Radiotherapy in Head & Neck MALT Lymphoma

Abstract 1083: A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

**18:35 – 18:45 hs. Dr. Ariel Gómez Palacios,
Centro de Radioterapia Dean Funes, Córdoba**

Abstract 1104: Is Bridging Radiation (RT) Safe with B Cell Maturation Antigen-targeting Chimeric Antigenic Receptor T Cells (CART-BCMA) Therapy?

Abstract 1105: Bridging Radiotherapy before CAR-T for High Grade Lymphoma — Feasibility and Efficacy

18:45 – 18:55 hs. Dr. Miguel Castiglioni, Instituto de Tumores Rosario, Santa Fe

Abstract 1108: Effective Pain Control with Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients with Painful Osseous Lesions

Abstract 1109: Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

18:55 – 19:25 hs. Mesa de Discusión:

Coordinador: Dr. Juan Galarraga (RT)

Panelistas: Dra. Carolina Fernández Bibiloni, Dr. Oscar Gómez Orrego (RT),

Dr. Luis Carvajal (RT), Dr. Miguel Castiglioni (RT),

Dr. Ariel Gómez Palacios (RT)

Dra. Astrid Pavlosky, Onco-Hematología,

Centro de Hematología Pavlovsky, Buenos Aires

19:25 – 19:45 hs. Simposio Craveri

Dr. Héctor Del Valle, Buenos Aires

Tema: "Manejo Terapéutico de la Radiodermatitis:

Propiedades de las emulsiones a base de Trolamina"

19:45 – 20:55 hs. Módulo 6: Cáncer Ginecológico

19:45 – 19:50 hs. Presidente: Dr. Mauro Mattio, Vidt Centro Médico, Buenos Aires

Coordinadora: Dra. Higinia Cardenes,

Weill Cornell University, New York, USA

Disertantes:

19:50 – 20:00 hs. Dr. Gastón Lemoine, Instituto de Radiaciones, Salta

Abstract 2: Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): Final Analysis

Abstract 234: Hyperthermia Combined with Concurrent Radiochemotherapy for 373 Patients with Cervical Cancer Stage IB-IV

20:00 – 20:15 hs. Dr. Emiliano Lissandrello, Instituto Mevaterapia, Buenos Aires

Abstract 238: Assessment of Impact of Bone Marrow Sparing for Hematological and Gastrointestinal Toxicities in Cervical Cancer with External Beam Radiation Therapy

Abstract 105: Is the Risk of Substantial LVSI in Stage I Endometrial Cancer Similar to PORTEC in the North American Population? - A Single Institution Study

Abstract 106: Utilizing Immune Profiles to Predict Pelvic Failure in Endometrial Cancer

20:15 – 20:25 hs. Dr. José Luis Asís, Centro Oncológico Riojano Integral, La Rioja

Abstract 233: Elective inguinal node irradiation is not necessary in cervical cancer invading lower third of vagina

Abstract 3024: Prognostic Significance of Negative Conversion of High-Risk Human Papillomavirus DNA After Treatment in Cervical Cancer Patients

20:25 – 20:55 hs. Mesa de Discusión:

Coordinadora: Dra. Higinia Cardenes (RT)

Panelistas: Dr. Mauro Mattio (RT), Dr. Gastón Lemoine (RT),

Dr. Emiliano Lisandrello (RT), Dr. José Luis Asís (RT)

Dra. Liliana Zamora, Oncología Clínica, Hospital Italiano, Buenos Aires

Dr. Diego Odetto, Cirugía Oncológica, Hospital Italiano, Buenos Aires

17:00 – 18:10 hs. Módulo 7: Cáncer de Mama

17:00 – 17:05 hs. Presidente: A Confirmar

Coordinador: Dr. Gustavo Sarría, Instituto Nacional de
Enfermedades Neoplásicas (INEN), Lima, Perú

Disertantes:

17:05 – 17:15 hs. Dra. Vanesa Krakobsky, Instituto Mevaterapia, Buenos Aires

Abstract 19: First 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost Versus 3-D-Conformal Radiotherapy with Consecutive Boost for Breast Cancer Patients

Abstract 52: De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost?

17:15 – 17:25 hs. Dra. Verónica Vázquez Balcarce, CEDITRA, Buenos Aires

Abstract 24: Patient reported experience with treatment modalities and safety of adjuvant breast radiotherapy- First results of the randomized HYPOSIB – study

Abstract 25: Defining the Optimal Dose for 3D-Conformal Accelerated Partial Breast Irradiation (APBI): 10-years Follow Up of a Dose-Escalation Trial

17:25 – 17:35 hs. Dra. Patricia Bruno, CEPROR, Villa María, Córdoba

Abstract 20: Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial

Abstract 21: Development and Internal Validation of an NTCP-Model for Acute Coronary Events after Breast Cancer Radiotherapy: First Results of the Medirad Brace Study

17:35 – 17:40 hs. Dra. María Fernanda Díaz Vázquez,
Centro de Radioterapia Dean Funes, Córdoba

Abstract 49: Heterogeneity in Outcomes Among Women with Clinically Node-Positive Breast Cancer and Axillary Pathologic Complete Response: An Analysis of NSABP B18, B27, B40, and B41

17:40 – 18:10 hs. Mesa de Discusión:

Coordinador: Dr. Gustavo Sarría (RT)

Panelistas: Dra. Vanesa Krakobsky (RT), Dra. Verónica Vázquez Balcarce (RT),
Dra. Patricia Bruno (RT); Dra. María Fernanda Díaz Vázquez RT
Dr. Ernesto Korbenfeld, **Oncología Clínica**, Hospital Británico, Buenos Aires
Dr. Juan Isetta, **Mastología**, Hospital Británico, Buenos Aires

Organizado por el Capítulo de Jóvenes Radioterapeutas de SATRO

18:10 – 19:05 hs. Módulo 8: Cuidados Paliativos

18:10 – 18:15 hs. Presidente: Dra. Luz Font Olivier, Terapia Radiante, La Plata, Bs. As.

Coordinadores: Dra. María José Girola, Vidt Centro Médico, Bs. As.
Dr. Javier Otero, Hospital Universitario Austral, BA

Disertantes:

18:15 – 18:20 hs. Dr. Lucas Staringer, Instituto Mevaterapia, Buenos Aires

Abstract 182: Phase II Clinical Trial of Stereotactic Body Radiotherapy for Painful Non-Spine Bone Metastases

18.20 – 18:30 hs. Dra. Ofelia Pérez Conci,
Centro de Radioterapia Dean Funes, Córdoba

Abstract 185: Safety and efficacy of multi-site stereotactic body radiotherapy and pembrolizumab for patients with large, treatment-refractory tumors

Abstract LBA2: CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases

18:30 – 18:35 hs. Dra. Clara Rojas, Vidt Centro Médico, Buenos Aires

Abstract 184: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial

18:35 – 19:05 hs. Mesa de Discusión:

Coordinadores: Dra. María José Girola (RT) – Dr. Javier Otero (RT)

Panelistas: Dra. Luz Font Olivier (RT), Dr. Lucas Staringer (RT),
Dra. Ofelia Pérez Conci (RT), Dra. Clara Rojas (RT)
Dra. Florencia Sarru, **Oncología Clínica**,
Clínica San Jorge, Ushuaia, Tierra del Fuego
Dr. Martín Miralles, **Médico Cuidados Paliativos**,
Hospital Español, La Plata, Buenos Aires

19:05 – 19:25 hs. Sesión Presidencial

Dr. Gustavo Ferraris

Centro de Radioterapia Dean Funes, Córdoba

Tema: Oligometástasis: de la Biología al Tratamiento

19:25 – 19:35 hs. Recertificación

Lectura de Nómina de Médicos Recertificados

19:35 – 20:50 hs. Módulo 9: Sistema Nervioso Central

19:35 – 19:40 hs. Presidente: Dra. Ana Martínez, Vidt Centro Médico, Buenos Aires

**Coordinadores: Dr. Ignacio Sisamón, Centro de Oncología y
Radioterapia, Mar del Plata, Buenos Aires**

**Dr. Lucas Causa,
Centro de Radioterapia Dean Funes, Córdoba**

Disertantes:

19:40 – 19:45 hs. Dra. Cecilia Díaz, Terapia Radiante, La Plata, Buenos Aires

Abstract 39: Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial

19:45 – 19:50 hs. Dr. Franco Schnitman, UNITER, Paraná, Entre Ríos

Abstract 40: A phase 2 study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with concomitant and adjuvant Metformin and Temozolomide (TMZ) in patients with Glioblastoma

19:50 – 19:55 hs. Dr. Diego Gronovich, Vidt Centro Médico, Buenos Aires

Abstract 41: Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial

19:55 – 20:00 hs. Dra. Silvia Hansing, Centro Oncológico Integral "COI", Neuquén

Abstract 42: Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001

(Continúa) 

19:35 – 20:50 hs. Módulo 9: Sistema Nervioso Central (Continuación)

20:00 – 20:05 hs. Dr. Ignacio Abregú, Centro de Radioterapia, San Juan

Abstract 1124: Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib

20:05 – 20:10 hs. Dr. Martín Fortte, Sanatorio Belgrano, Mar del Plata, Bs. As.

Abstract 1155: Timing of Adjuvant Radiotherapy in Atypical Meningiomas

20:10 – 20:15 hs. Dra. María May, CONICET, Buenos Aires

Abstract 1156: Prospective Evaluation of Microscopic Extension using Macropathology in Glioma Patients: Determination of Optimal Clinical Target Volume Margins for Radiotherapy

20:15 – 20:20 hs. Dr. Marcos Santos, Clínica CONFIAR, Goiania, Brasil

Abstract 1159: Biomarkers of Post-radiation Cerebellar Injury Are Associated with Neurocognitive Decline in Primary Brain Tumor Patients

20:20 – 20:50 hs. Mesa de Discusión:

Coordinadores: Dr. Ignacio Sisamón (RT), Dr. Lucas Causa (RT)

Panelistas: Dra. Ana Martínez (RT), Dra. Cecilia Díaz (RT), Dr. Franco Schnitman (RT), Dr. Diego Gronovich (RT), Dra. Silvia Hansing (RT), Dr. Ignacio Abregú (RT), Dr. Martín Fortte (Neurocirugía), Sanatorio Belgrano, Mar del Plata, Bs. As.
Dra. María May (Patología), CONICET, Buenos Aires
Dr. Marcos Santos (Oncología), Clínica CONFIAR, Goiania, Brasil.

20:50 hs. Acto de Cierre del V Best of ASTRO



Sociedad Argentina de Terapia Radiante Oncológica



SCIENCE OF TODAY
HOPE FOR TOMORROW

Argentina